PURPOSE: To quantify the relative and absolute excess risks (AER) of site-specific second cancers, in particular solid tumors, among long-term survivors of Hodgkin's disease (HD) and to assess risks according to age at HD diagnosis, attained age, and time since initial treatment. PATIENTS AND METHODS: Data from 32,591 HD patients (1,111 25-year survivors) reported to 16 population-based cancer registries in North America and Europe (1935 to 1994) were analyzed. RESULTS: Two thousand one hundred fifty-three second cancers (observed-to-expected ratio [O/E] = 2.3; 95% confidence interval [CI] = 2.2 to 2.4), including 1,726 solid tumors (O/E = 2.0; 95% CI, 1.9 to 2.0) were reported. Cancers of the lung (observed [Obs] = 377; O/E = 2.9), digestive tract (Obs = 376; O/E = 1.7), and female breast (Obs = 234; O/E = 2.0) accounted for the largest number of subsequent malignancies. Twenty-five years after HD diagnosis, the actuarial risk of developing a solid tumor was 21.9%. The relative risk of solid neoplasms decreased with increasing age at HD diagnosis, however, patients aged 51 to 60 years at HD diagnosis sustained the highest cancer burden (AER = 79.2/10,000 patients/year). After a progressive rise in relative risk and AER of all solid tumors over time, there was an apparent downturn in risk at 25 years. Temporal trends and treatment group distribution for cancers of the esophagus, stomach, rectum, female breast, bladder, thyroid, and bone/connective tissue were suggestive of a radiogenic effect. CONCLUSION: Significantly increased risks of second cancers were observed in all HD age groups. Although significantly elevated risks of stomach, female breast, and uterine cervix cancers persisted for 25 years, an apparent decrease in relative risk and AER of solid tumors at other sites is suggested.
PURPOSE: To quantify the relative and absolute excess risks (AER) of site-specific second cancers, in particular solid tumors, among long-term survivors of Hodgkin's disease (HD) and to assess risks according to age at HD diagnosis, attained age, and time since initial treatment. PATIENTS AND METHODS: Data from 32,591 HDpatients (1,111 25-year survivors) reported to 16 population-based cancer registries in North America and Europe (1935 to 1994) were analyzed. RESULTS: Two thousand one hundred fifty-three second cancers (observed-to-expected ratio [O/E] = 2.3; 95% confidence interval [CI] = 2.2 to 2.4), including 1,726 solid tumors (O/E = 2.0; 95% CI, 1.9 to 2.0) were reported. Cancers of the lung (observed [Obs] = 377; O/E = 2.9), digestive tract (Obs = 376; O/E = 1.7), and female breast (Obs = 234; O/E = 2.0) accounted for the largest number of subsequent malignancies. Twenty-five years after HD diagnosis, the actuarial risk of developing a solid tumor was 21.9%. The relative risk of solid neoplasms decreased with increasing age at HD diagnosis, however, patients aged 51 to 60 years at HD diagnosis sustained the highest cancer burden (AER = 79.2/10,000 patients/year). After a progressive rise in relative risk and AER of all solid tumors over time, there was an apparent downturn in risk at 25 years. Temporal trends and treatment group distribution for cancers of the esophagus, stomach, rectum, female breast, bladder, thyroid, and bone/connective tissue were suggestive of a radiogenic effect. CONCLUSION: Significantly increased risks of second cancers were observed in all HD age groups. Although significantly elevated risks of stomach, female breast, and uterine cervix cancers persisted for 25 years, an apparent decrease in relative risk and AER of solid tumors at other sites is suggested.
Authors: Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan Journal: Ann Intern Med Date: 2012-06-05 Impact factor: 25.391
Authors: Paul Craig Nathan; Kirsten Kimberlie Ness; Martin Christopher Mahoney; Zhenghong Li; Melissa Maria Hudson; Jennifer Sylene Ford; Wendy Landier; Marilyn Stovall; Gregory Thomas Armstrong; Tara Olive Henderson; Leslie L Robison; Kevin Charles Oeffinger Journal: Ann Intern Med Date: 2010-10-05 Impact factor: 25.391
Authors: Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Woodrow A Wells; Jane N Winter; Sandra J Horning; A Rashid Dar; Chaim Shustik; Douglas A Stewart; Michael Crump; Marina S Djurfeldt; Bingshu E Chen; Lois E Shepherd Journal: N Engl J Med Date: 2011-12-11 Impact factor: 91.245
Authors: Sarah B Scarboro; Marilyn Stovall; Allen White; Susan A Smith; Derek Yaldo; Stephen F Kry; Rebecca M Howell Journal: Phys Med Biol Date: 2010-11-12 Impact factor: 3.609
Authors: M Krausch; A Raffel; M Anlauf; M Schott; N Lehwald; A Krieg; F Kröpil; K Cupisti; W T Knoefel Journal: Endocrine Date: 2013-03-14 Impact factor: 3.633